 |
 |
 |
 |
|
| |
 |
| Reports on Overseas' Conferences and
Meetings |
|
| |
|
| |
| Bulletin report
on the Peripheral T-cell Lymphoma Forum |
| Kunihiro Tsukasaki,
Department of Molecular Medicine and Hematology |
The Peripheral T-cell Lymphoma
Forum was held in September 18-20, 2008,
at Washington, DC. This forum provided a
platform for discussion about the diagnosis,
classification, current treatment options,
and novel approaches for PTCL that include
more than ten disease entities. I attended
the meeting because the incidence of peripheral
T-cell lymphomas (PTCL), a type of non-Hodgkin’s
lymphoma (NHL), is high in Japan especially
south-west coast of Kyusyu.
In the session of state of arts on the treatment
for PTCL, Dr. Tobinai at National Cancer Center,
Japan, presented our data on adult T-cell
leukemia-lymphoma (ATL). A phase 3 study of
118 ATL patients compared biweekly CHOP with
multiagent chemotherapy of VCAP-AMP-VECP,
supported by G-CSF. The complete response
rate was 40% in the VCAP-AMP-VECP arm and
25% in the CHOP arm. He concluded that the
median survival time of 13 months with VCAPAMP-VECP
as compared to 11 months with biweekly CHOP
is still not satisfactory, , but this should
be the basis for future study in the treatmentof
ATL.
In contrast to rituximab, anti-CD20 monoclonal
antibody, for the treatment of B-cell lymphoma,
no molecular targeting agent is available
for PTCL. In the meeting, several kinds of
promising agents for the diseases were presented,
including monoclonal antibodies targeting
CD2, CD4, CD25, CD52 and CCR4, histone deacetylase
inhibitor, proteasome inhibitor, novel nucleoside
analogs, novel folate analogs and signal transduction
inhibitors. We presented the preliminary results
of a phase 1 trial of nobel agent, ant-CCR4
antibody ongoing in Japan. CCR4 is a chemokine
receptor expressed in most ATL and about one
third of unspecified PTCL, The results showed
relative safety and some efficacy of the antibody.
Among other topics, allogeneic stem cell transplantation
for young patient and praratrexate, a novel
folate analog, were apparently promising.
The next Peripheral T-cell Lymphoma Forum
will be held in Bologna, Italy, in next year.
. |
|
|
|
|
|
| |
|
|
|
